Cervical cancer, geographical inequalities, prevention and barriers in resource depleted countries
- PMID: 35251344
- PMCID: PMC8850967
- DOI: 10.3892/ol.2022.13233
Cervical cancer, geographical inequalities, prevention and barriers in resource depleted countries
Abstract
Cervical cancer (CC) remains a current global issue, with >90% of cervical cancer cases being attributed to human papilloma virus (HPV). The highest burden of cervical cancer is reported in resource-depleted geographical areas with a high incidence of HPV infection. Recent developments in primary prevention include vaccinations against specific strains of HPV and the psychoeducation of the public. Yet, despite the availability of vaccinations, there is high incidence of both HPV and cervical cancer in developing countries, which is attributed to a multitude of barriers including inaccessibility to expensive vaccines. With regards to secondary prevention, progress is actively being made to develop more effective methods of screening and to specifically address the needs of low-income countries. In the past few years, more novel screening methods, such as self-assessment kits, immunohistochemistry and methylation marker analysis, have been developed. Barriers to screening in resource-depleted countries include limited financial resources and infrastructure to develop screening programmes, a lack of screening programmes that are accessible to populations, inadequate training of healthcare teams and stigma related to medical examinations performed as part of screening. Developing primary and secondary prevention programs, as well as addressing the barriers involved in countries with low socioeconomic levels, can drastically reduce morbidity and mortality rates associated with cervical cancer, thus reducing the burden associated with this gynaecological malignancy.
Keywords: barriers; cervical cancer; human papilloma virus self-sampling; methylation markers; primary prevention; psychoeducation; screening; vaccinations.
Copyright: © Bogdanova et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Current Status and Future Perspectives of Molecular Prevention Strategies for Cervical Cancers.Indian J Surg Oncol. 2020 Dec;11(4):752-761. doi: 10.1007/s13193-019-00910-z. Epub 2019 Mar 18. Indian J Surg Oncol. 2020. PMID: 33299288 Free PMC article. Review.
-
Eliminating Cervical Cancer in Mali and Senegal, Two Sub-Saharan Countries: Insights and Optimizing Solutions.Vaccines (Basel). 2020 Apr 14;8(2):181. doi: 10.3390/vaccines8020181. Vaccines (Basel). 2020. PMID: 32295116 Free PMC article. Review.
-
Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges.Minerva Ginecol. 2019 Oct;71(5):365-371. doi: 10.23736/S0026-4784.19.04468-X. Minerva Ginecol. 2019. PMID: 31698891 Review.
-
Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.World J Clin Oncol. 2015 Dec 10;6(6):281-90. doi: 10.5306/wjco.v6.i6.281. World J Clin Oncol. 2015. PMID: 26677441 Free PMC article. Review.
-
Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.Vaccine. 2013 Dec 29;31 Suppl 5:F53-9. doi: 10.1016/j.vaccine.2012.06.070. Vaccine. 2013. PMID: 24331748 Review.
Cited by
-
Risk factors for the development of cervical cancer: analysis of the evidence.Front Oncol. 2024 May 23;14:1378549. doi: 10.3389/fonc.2024.1378549. eCollection 2024. Front Oncol. 2024. PMID: 38846977 Free PMC article. Review.
-
The association of cervical cancer screening and quality of care: A systematic analysis of the Global Burden of Disease Study 2019.J Glob Health. 2023 Aug 25;13:04090. doi: 10.7189/jogh.13.04090. J Glob Health. 2023. PMID: 37622720 Free PMC article.
-
Impact of Cholecalciferol Supplementation on Radiotherapy Outcomes in Advanced Cervical Cancer.Med Sci Monit. 2025 Mar 24;31:e945964. doi: 10.12659/MSM.945964. Med Sci Monit. 2025. PMID: 40123110 Free PMC article. Clinical Trial.
-
Cervical Cancer Prophylaxis-State-of-the-Art and Perspectives.Healthcare (Basel). 2022 Jul 17;10(7):1325. doi: 10.3390/healthcare10071325. Healthcare (Basel). 2022. PMID: 35885852 Free PMC article. Review.
-
Optical imaging for screening and early cancer diagnosis in low-resource settings.Nat Rev Bioeng. 2024 Jan;2(1):25-43. doi: 10.1038/s44222-023-00135-4. Epub 2023 Dec 22. Nat Rev Bioeng. 2024. PMID: 39301200 Free PMC article.
References
-
- Globocan 2020, corp-author. New Global Cancer Data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data. [ September 18; 2021 ];Uicc.org. 2021
-
- Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM, New Mexico HPV Pap Registry Steering Committee Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical Neoplasia. Cancer Epidemiol Biomarkers Prev. 2019;28:1816–1824. doi: 10.1158/1055-9965.EPI-19-0239. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous